肝细胞癌在68Ga-DOTATATE PET/CT上模拟神经内分泌肿瘤转移
本文报告一例65岁男性,既往因高分化胰腺神经内分泌肿瘤行Whipple手术,CT发现新发肝脏病灶,行68Ga-DOTATATE PET/CT评估生长抑素受体(SSR)表达以再分期,病灶呈SSR强阳性,初判为神经内分泌肿瘤转移,但后续病理证实为肝细胞癌。提示肝细胞癌可表现为DOTATATE高摄取,应纳入SSR阳性肝脏病灶的鉴别诊断。
要点
- 68Ga-DOTATATE高摄取的肝脏病灶并非特异于神经内分泌肿瘤转移,肝细胞癌亦可高摄取。
- 有神经内分泌肿瘤病史者出现新发肝脏SSR阳性病灶时,需病理证实以排除肝细胞癌等其它DOTATATE亲和性肿瘤。
- 本病例为65岁男性,Whipple术后,CT新发肝脏病灶,DOTATATE PET/CT示病灶SSR强阳性。
核心结论
- 68Ga-DOTATATE PET/CT上SSR强阳性的肝脏病灶并非神经内分泌肿瘤转移所特有,肝细胞癌也可表现为DOTATATE高摄取,应纳入鉴别诊断。
研究设计与样本
- 个案报告:一例65岁男性,高分化胰腺神经内分泌肿瘤Whipple术后,CT新发肝脏病灶,行68Ga-DOTATATE PET/CT评估SSR表达并再分期,后续经病理确诊。
主要发现
- 68Ga-DOTATATE PET/CT显示该肝脏病灶SSR强阳性,初判为神经内分泌肿瘤转移;后续病理证实为肝细胞癌。
临床怎么用
- 对有神经内分泌肿瘤病史、DOTATATE PET/CT示肝脏SSR阳性病灶的患者,应警惕肝细胞癌可能,必要时行病理证实,避免仅凭DOTATATE摄取误判为转移。
局限性
- 本文为单个病例报告,不能据此推断肝细胞癌DOTATATE摄取的发生率或鉴别阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ga-DOTATATE is a radiolabeled somatostatin analog used for the detection and characterization of somatostatin receptor (SSR)-overexpressing tumors, particularly well-differentiated neuroendocrine tumors. We present a case of a 65-year-old man with well-differentiated pancreatic neuroendocrine tumor post-Whipple surgery and a new liver lesion on CT. Ga-DOTATATE PET/CT was performed for SSR characterization and restaging, which demonstrated the lesion to be intensely SSR positive and interpreted as a neuroendocrine metastasis. However, subsequent pathology proved the lesion to be a hepatocellular carcinoma. This case adds hepatocellular carcinoma as a potentially DOTATATE-avid malignancy to be considered in the differential diagnoses of SSR-positive liver lesions.
引用
- Ulaner GA, Bodei L. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2019. PMID: 30688738. doi:10.1097/RLU.0000000000002467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。